Roivant Sciences Ltd.2025财年实现净利润-5.45亿美元，同比减少112.53%

市场透视2025-05-31

5月31日，Roivant Sciences Ltd.（ROIV.US）公布财报，公告显示公司2025财年净利润为-5.45亿美元，同比减少112.53%；其中营业收入为29.05百万美元，同比减少76.76%，每股基本收益为-0.24美元。从资产负债表来看，Roivant Sciences Ltd.（ROIV.US）总负债2.50亿美元，其中短期债务9.84百万美元，资产负债比为21.75，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539270073?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-31 03:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2539270073","market":"us","top_or_hot":-1,"title":"Roivant Sciences Ltd.2025财年实现净利润-5.45亿美元，同比减少112.53%","media":"市场透视","content":"<div>\n<p>5月31日，Roivant Sciences Ltd.（ROIV.US）公布财报，公告显示公司2025财年净利润为-5.45亿美元，同比减少112.53%；其中营业收入为29.05百万美元，同比减少76.76%，每股基本收益为-0.24美元。从资产负债表来看，Roivant Sciences Ltd.（ROIV.US）总负债2.50亿美元，其中短期债务9.84百万美元，资产负债比为21.75，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531030052a6f3b50d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant Sciences Ltd.2025财年实现净利润-5.45亿美元，同比减少112.53%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant Sciences Ltd.2025财年实现净利润-5.45亿美元，同比减少112.53%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-31 03:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531030052a6f3b50d&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月31日，Roivant Sciences Ltd.（ROIV.US）公布财报，公告显示公司2025财年净利润为-5.45亿美元，同比减少112.53%；其中营业收入为29.05百万美元，同比减少76.76%，每股基本收益为-0.24美元。从资产负债表来看，Roivant Sciences Ltd.（ROIV.US）总负债2.50亿美元，其中短期债务9.84百万美元，资产负债比为21.75，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531030052a6f3b50d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531030052a6f3b50d&s=b","article_id":"2539270073","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531030052a6f3b50d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2539270073","pubTimestamp":1748631645,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月31日，Roivant Sciences Ltd.公布财报，公告显示公司2025财年净利润为-5.45亿美元，同比减少112.53%；其中营业收入为29.05百万美元，同比减少76.76%，每股基本收益为-0.24美元。从资产负债表来看，Roivant Sciences Ltd.总负债2.50亿美元，其中短期债务9.84百万美元，资产负债比为21.75，流动比率为33.56。机构评级：截至2025年5月31日，当前有8家机构对Roivant Sciences Ltd.目标价做出预测，其中目标均价为16.75美元，其中最低目标价为12.00美元，最高目标价为22.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"Roivant Sciences Ltd. achieved net profit of-US $545 million in fiscal 2025, a year-on-year decrease of 112.53%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"5月31日，Roivant Sciences Ltd.（ROIV.US）公布财报，公告显示公司2025财年净利润为-5.45亿美元，同比减少112.53%；其中营业收入为29.05百万美元，同比减少76.76%，每股基本收益为-0.24美元。从资产负债表来看，Roivant Sciences Ltd.（ROIV.US）总负债2.50亿美元，其中短期债务9.84百万美元，资产负债比为21.75，流动比率为33.56。机构评级：截至2025年5月31日，当前有8家机构对Roivant Sciences Ltd.目标价做出预测，其中目标均价为16.75美元，其中最低目标价为12.00美元，最高目标价为22.00美元。公司简介：Roivant Sciences Ltd是一家处于商业阶段的生物制药公司，致力于改善向患者提供医疗保健。该公司还孵化与其生物制药业务互补的发现阶段公司和健康科技初创企业。其药物候选VTAMA（tapinarof）是成人斑块型银屑病治疗药物，并处于商业阶段。在不同开发阶段中的其他药物候选包括：Batoclimab、IMVT-1402、Brepocitinib、Namilumab等。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539270073","isCrawlerRequest":true}